Bioventus (BVS) Competitors $6.93 0.00 (0.00%) As of 02:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsFinancialsSEC FilingsShort InterestTrendsBuy This Stock BVS vs. EYE, LMAT, LQDA, CNMD, ENOV, CDRE, AORT, NVCR, SSII, and ESTAShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include National Vision (EYE), LeMaitre Vascular (LMAT), Liquidia Technologies (LQDA), CONMED (CNMD), Enovis (ENOV), Cadre (CDRE), Artivion (AORT), NovoCure (NVCR), SS Innovations International (SSII), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry. Bioventus vs. Its Competitors National Vision LeMaitre Vascular Liquidia Technologies CONMED Enovis Cadre Artivion NovoCure SS Innovations International Establishment Labs National Vision (NASDAQ:EYE) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends. Which has more volatility & risk, EYE or BVS? National Vision has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Do insiders & institutionals hold more shares of EYE or BVS? 62.9% of Bioventus shares are owned by institutional investors. 2.7% of National Vision shares are owned by company insiders. Comparatively, 33.0% of Bioventus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate EYE or BVS? National Vision presently has a consensus target price of $24.73, suggesting a potential upside of 9.00%. Given National Vision's stronger consensus rating and higher possible upside, research analysts clearly believe National Vision is more favorable than Bioventus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score National Vision 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Bioventus 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is EYE or BVS more profitable? Bioventus has a net margin of -0.03% compared to National Vision's net margin of -0.75%. Bioventus' return on equity of 23.51% beat National Vision's return on equity.Company Net Margins Return on Equity Return on Assets National Vision-0.75% 3.56% 1.49% Bioventus -0.03%23.51%5.99% Which has stronger valuation & earnings, EYE or BVS? National Vision has higher revenue and earnings than Bioventus. National Vision is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNational Vision$1.82B0.98-$28.50M-$0.33-68.75Bioventus$573.28M0.99-$33.54M-$0.48-14.44 Does the media prefer EYE or BVS? In the previous week, National Vision had 25 more articles in the media than Bioventus. MarketBeat recorded 26 mentions for National Vision and 1 mentions for Bioventus. National Vision's average media sentiment score of 1.15 beat Bioventus' score of -1.50 indicating that National Vision is being referred to more favorably in the media. Company Overall Sentiment National Vision Positive Bioventus Very Negative SummaryNational Vision beats Bioventus on 9 of the 16 factors compared between the two stocks. Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$569.23M$153.72M$2.54B$9.68BDividend YieldN/AN/A2.57%4.14%P/E Ratio-14.44N/A22.2324.95Price / Sales0.9919.0386.4777.81Price / Cash6.814.1126.8658.58Price / Book3.041.5338.515.68Net Income-$33.54M-$66.04M$28.61M$265.58M7 Day Performance12.14%-1.26%1.70%2.52%1 Month PerformanceN/A9.28%1.46%1.86%1 Year PerformanceN/A271.09%30.28%24.27% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus1.0715 of 5 stars$6.93flatN/AN/A$569.23M$573.28M-14.441,200Earnings ReportEYENational Vision3.0353 of 5 stars$24.10-0.7%$24.18+0.4%+121.1%$1.91B$1.82B-73.0913,411Trending NewsEarnings ReportAnalyst ForecastLMATLeMaitre Vascular2.3881 of 5 stars$80.45-1.0%$97.83+21.6%+17.4%$1.81B$219.86M40.54490Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionLQDALiquidia Technologies3.4441 of 5 stars$18.59-0.5%$26.89+44.7%+79.9%$1.59B$14M-11.7650News CoverageInsider TradeCNMDCONMED3.9691 of 5 stars$50.18-1.9%$59.80+19.2%-19.9%$1.55B$1.33B14.183,900Dividend AnnouncementGap UpENOVEnovis3.2159 of 5 stars$25.81-3.7%$55.60+115.4%-29.8%$1.47B$2.11B-1.857,367Trending NewsEarnings ReportAnalyst ForecastCDRECadre2.9838 of 5 stars$32.64-1.0%$37.50+14.9%-5.1%$1.33B$559.81M34.352,284News CoverageEarnings ReportAnalyst RevisionAORTArtivion2.3101 of 5 stars$30.66-0.8%$32.40+5.7%+30.4%$1.31B$388.54M-61.341,600Trending NewsEarnings ReportAnalyst ForecastGap UpNVCRNovoCure4.5162 of 5 stars$11.12-3.9%$28.79+159.0%-40.1%$1.25B$630.16M-7.141,488Gap UpSSIISS Innovations InternationalN/A$6.40-5.7%N/AN/A$1.24B$22.13M0.004News CoveragePositive NewsESTAEstablishment Labs1.9332 of 5 stars$41.25-1.7%$54.83+32.9%+1.1%$1.19B$170.24M-13.311,018News CoverageEarnings Report Related Companies and Tools Related Companies EYE Alternatives LMAT Alternatives LQDA Alternatives CNMD Alternatives ENOV Alternatives CDRE Alternatives AORT Alternatives NVCR Alternatives SSII Alternatives ESTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BVS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
